FindMyKOL
Clinical trialNCT06177171Active, not recruitingPhase 1Interventional

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

NCT06177171 is a phase 1 interventional trial sponsored by Varun Monga, MBBS. As of 21 Nov 2026, it is active and no longer recruiting. It studies ASTX727 and Olaparib in ATM Gene Mutation, BRCA Mutation and 4 more conditions. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 7 Feb 2024 and a primary completion date of 31 Jan 2028. One of its registered investigators has a FindMyKOL profile.

SponsorVarun Monga, MBBSEnrollment13ATM Gene MutationBRCA MutationBRCA1 MutationBRCA2 MutationCheckpoint Kinase 2 Gene MutationPALB2 Gene Mutation
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06177171
FieldValue
Registry IDNCT06177171
StatusActive not recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorVarun Monga, MBBS
Enrollment13
Registered sites1
Countries1
ConditionsATM Gene Mutation, BRCA Mutation, BRCA1 Mutation, BRCA2 Mutation, Checkpoint Kinase 2 Gene Mutation and PALB2 Gene Mutation
DrugsASTX727 and Olaparib
Start7 Feb 2024
Primary completion31 Jan 2028
Study completion31 Jan 2028
Last update posted20 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2 (CHEK2) mutations).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • University of California, San Francisco

    San Francisco

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06177171

Each answer restates registry values shown on this page.

What is NCT06177171?

NCT06177171 is a phase 1 interventional trial sponsored by Varun Monga, MBBS. It studies ASTX727 and Olaparib in ATM Gene Mutation, BRCA Mutation and 4 more conditions.

Is NCT06177171 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT06177171?

The registry names Varun Monga, MBBS (principal investigator, University of California, San Francisco) as the overall official.

Where does NCT06177171 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06177171 study?

The registered drug and biological interventions are ASTX727 and Olaparib.

When is NCT06177171 expected to complete?

The registry lists a primary completion date of 31 Jan 2028 and a study completion date of 31 Jan 2028. The sponsor last updated the record on 20 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.